Search Results - "Janczewska, Ewa"

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV by Ferenci, Peter, Bernstein, David, Lalezari, Jacob, Cohen, Daniel, Luo, Yan, Cooper, Curtis, Tam, Edward, Marinho, Rui T, Tsai, Naoky, Nyberg, Anders, Box, Terry D, Younes, Ziad, Enayati, Pedram, Green, Sinikka, Baruch, Yaacov, Bhandari, Bal Raj, Caruntu, Florin Alexandru, Sepe, Thomas, Chulanov, Vladimir, Janczewska, Ewa, Rizzardini, Giuliano, Gervain, Judit, Planas, Ramon, Moreno, Christophe, Hassanein, Tarek, Xie, Wangang, King, Martin, Podsadecki, Thomas, Reddy, K. Rajender

“…Among previously untreated patients with HCV genotype 1 infection, three new antiviral agents, with or without ribavirin, resulted in high rates of sustained…”
Get full text

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial by Manns, Michael, Prof, Marcellin, Patrick, Prof, Poordad, Fred, Prof, de Araujo, Evaldo Stanislau Affonso, PhD, Buti, Maria, Prof, Horsmans, Yves, Prof, Janczewska, Ewa, MD, Villamil, Federico, Prof, Scott, Jane, PhD, Peeters, Monika, MSc, Lenz, Oliver, PhD, Ouwerkerk-Mahadevan, Sivi, PhD, De La Rosa, Guy, MD, Kalmeijer, Ronald, MD, Sinha, Rekha, PhD, Beumont-Mauviel, Maria, PhD

“…Summary Background Pegylated interferon (peginterferon) alfa 2a or 2b plus ribavirin regimens were the standard of care in patients with hepatitis C virus…”
Get full text

Lifestyle and Quality of Life of Women with Diagnosed Hypothyroidism in the Context of Metabolic Disorders by Janota, Barbara, Szczepanska, Elzbieta, Noras, Kinga, Janczewska, Ewa

“…The lifestyle causes of metabolic disorders in patients with hypothyroidism should be investigated. We aimed to assess the lifestyle and quality of life of…”
Get full text

Lifestyle and Quality of Life of Women Diagnosed with Hypothyroidism in the Context of Non-Alcoholic Fatty Liver by Janota, Barbara, Adamek, Brygida, Szczepańska, Elżbieta, Biernacki, Krzysztof, Janczewska, Ewa

“…Interconnections between hypothyroidism and metabolic disturbances manifesting in the liver and body composition have not yet been comprehensively analyzed in…”
Get full text

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens by Tronina, Olga, Brzdęk, Michał, Zarębska-Michaluk, Dorota, Dybowska, Dorota, Lorenc, Beata, Janczewska, Ewa, Mazur, Włodzimierz, Parfieniuk-Kowerda, Anna, Piekarska, Anna, Krygier, Rafał, Klapaczyński, Jakub, Berak, Hanna, Jaroszewicz, Jerzy, Garlicki, Aleksander, Tomasiewicz, Krzysztof, Citko, Jolanta, Flisiak, Robert

“…Direct-acting antivirals (DAA) regimens have provided hope for eliminating hepatitis C virus (HCV) infection. Patients following ineffective therapy with DAA,…”
Get full text

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis by Schramm, Christoph, Wedemeyer, Heiner, Mason, Andrew, Hirschfield, Gideon M., Levy, Cynthia, Kowdley, Kris V., Milkiewicz, Piotr, Janczewska, Ewa, Malova, Elena Sergeevna, Sanni, Johanne, Koo, Phillip, Chen, Jin, Choudhury, Subhajit, Klickstein, Lloyd B., Badman, Michael K., Jones, David

“…The safety, tolerability, and efficacy of the non-bile acid farnesoid X receptor agonist tropifexor were evaluated in a phase II, double-blind,…”
Get full text

JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1 by Zeuzem, Stefan, Bourgeois, Stefan, Greenbloom, Susan, Buti, Maria, Aghemo, Alessio, Lampertico, Pietro, Janczewska, Ewa, Lim, Seng Gee, Moreno, Christophe, Buggisch, Peter, Tam, Edward, Corbett, Chris, Willems, Wouter, Vijgen, Leen, Fevery, Bart, Ouwerkerk‐Mahadevan, Sivi, Ackaert, Oliver, Beumont, Maria, Kalmeijer, Ronald, Sinha, Rekha, Biermer, Michael

“…The combination of three direct‐acting antiviral agents (AL‐335, odalasvir, and simeprevir: JNJ‐4178 regimen) for 6 or 8 weeks demonstrated good efficacy and…”
Get full text

Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors by Hammitt, Laura L., Quinn, Dean, Janczewska, Ewa, Pasquel, Francisco J., Tytus, Richard, Reddy, K. Rajender, Abarca, Katia, Khaertynova, Ilsiyar M., Dagan, Ron, Dawson, Rachel, McCauley, Jennifer, Shekar, Tulin, Fu, Wei, Pedley, Alison, Sterling, Tina, Tamms, Gretchen, Musey, Luwy, Buchwald, Ulrike K.

“…Immunocompetent adults with certain medical and behavioral factors are at increased risk of pneumococcal disease. In some countries, sequential vaccination…”
Get full text

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy by Jaroszewicz, Jerzy, Pabjan, Paweł, Laurans, Łukasz, Mazur, Włodzimierz, Socha, Łukasz, Tronina, Olga, Parczewski, Miłosz, Flisiak, Robert, Dobracka, Beata, Sitko, Marek, Dybowska, Dorota, Janczewska, Ewa, Tudrujek-Zdunek, Magdalena, Simon, Krzysztof, Buczyńska, Iwona, Zarębska-Michaluk, Dorota, Klapaczyński, Jakub

“…Background and Aim. The development of interferon- (IFN-) free regimens substantially improved efficacy of treatment for HCV, but despite excellent…”
Get full text

Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1 by Jacobson, Ira, Zeuzem, Stefan, Flisiak, Robert, Knysz, Brygida, Lueth, Stefan, Zarebska-Michaluk, Dorota, Janczewska, Ewa, Ferenci, Peter, Diago, Moises, Zignego, Anna Linda, Safadi, Rifaat, Baruch, Yaacov, Abdurakhmanov, Dzhamal, Shafran, Stephen, Thabut, Dominique, Bruck, Rafael, Gadano, Adrian, Thompson, Alexander James, Kopit, Justin, McPhee, Fiona, Michener, Tracy, Hughes, Eric A, Yin, Philip D, Noviello, Stephanie

“…AIM: To evaluate daclatasvir vs telaprevir, each combined with peginterferon alfa-2a/ribavirin(peg IFN/RBV), in treatment-naive hepatitis C virus(HCV)…”
Get full text

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8 week regimen in a real-world setting by Zarębska-Michaluk, Dorota, Piekarska, Anna, Jaroszewicz, Jerzy, Klapaczyński, Jakub, Sitko, Marek, Tudrujek-Zdunek, Magdalena, Tomasiewicz, Krzysztof, Belica-Wdowik, Teresa, Pabjan, Paweł, Lorenc, Beata, Czauż-Andrzejuk, Agnieszka, Tronina, Olga, Krygier, Rafał, Dobracki, Witold, Buczyńska, Iwona, Simon, Krzysztof A., Dybowska, Dorota, Halota, Waldemar, Pawłowska, Małgorzata, Citko, Jolanta, Laurans, Łukasz, Mazur, Włodzimierz, Janczewska, Ewa, Socha, Łukasz, Deroń, Zbigniew, Berak, Hanna, Flisiak, Robert

“…Introduction Non-cirrhotic treatment-naive hepatitis C patients infected with genotype 1 can be treated with ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks, but…”
Get full text

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study by Janczewska, Ewa, Zarębska-Michaluk, Dorota, Berak, Hanna, Piekarska, Anna, Gietka, Andrzej, Dybowska, Dorota, Mazur, Włodzimierz, Belica-Wdowik, Teresa, Dobracki, Witold, Tudrujek-Zdunek, Magdalena, Deroń, Zbigniew, Buczyńska, Iwona, Sitko, Marek, Czauż-Andrzejuk, Agnieszka, Lorenc, Beata, Białkowska-Warzecha, Jolanta, Citko, Jolanta, Laurans, Łukasz, Jaroszewicz, Jerzy, Socha, Łukasz, Tronina, Olga, Adamek, Brygida, Horban, Andrzej, Halota, Waldemar, Baka-Ćwierz, Barbara, Tomasiewicz, Krzysztof, Simon, Krzysztof, Garlicki, Aleksander, Wawrzynowicz-Syczewska, Marta, Flisiak, Robert

“…According to the EASL and AASLD guidelines, the recommended treatment for patients who failed to achieve a sustained virologic response (SVR) on prior…”
Get full text

Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study by Gane, Edward J, DeJesus, Edwin, Janczewska, Ewa, George, Jacob, Diago, Moises, Da Silva, Mariliza Hendrique, Reesink, Henk, Nikitin, Igor, Hinrichsen, Holger, Bourgeois, Stefan, Ferenci, Peter, Shukla, Umesh, Kalmeijer, Ronald, Lenz, Oliver, Fevery, Bart, Corbett, Chris, Beumont, Maria, Jessner, Wolfgang

“…This Phase 3, open-label, rollover study (NCT01323244) investigated the efficacy and safety of simeprevir plus peginterferon α-2a (PegIFNα-2a) and ribavirin…”
Get full text

1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL by Manns, M, Marcellin, P, Fred Poordad, F.P, Stanislau Affonso de Araujo, E, Buti, M, Horsmans, Y, Ewa Janczewska, E.J, Villamil, F, Peeters, M, Lenz, O, Ouwerkerk-Mahadevan, S, Kalmeijer, R, Beumont-Mauviel, M

Get full text

Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-β1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C by Janczewska-Kazek, Ewa

“…R5; AIM: To assess the role of transforming growth factor-β1(TGF-β1), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (Bfgf) in…”
Get full text

Hypothyroidism and non-alcoholic fatty liver disease: A coincidence or a causal relationship? by Janota, Barbara, Szczepańska, Elżbieta, Adamek, Brygida, Janczewska, Ewa

“…Non-alcoholic fatty liver disease (NAFLD) is a global problem. It may be caused by metabolic and hormonal disorders, including hypothyroidism. However,…”
Get full text

Evaluation of the nutritional status of patients with liver cirrhosis by Janota, Barbara, Krupowicz, Aneta, Noras, Kinga, Janczewska, Ewa

“…Progressive malnutrition coexists with liver diseases, particularly in patients with cirrhosis. Early diagnosis of malnutrition in patients with advanced…”
Get full text

Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection by Yuen, Man-Fung, Lim, Seng-Gee, Plesniak, Robert, Tsuji, Keiji, Janssen, Harry L.A., Pojoga, Cristina, Gadano, Adrian, Popescu, Corneliu P., Stepanova, Tatyana, Asselah, Tarik, Diaconescu, Gheorghe, Yim, Hyung Joon, Heo, Jeong, Janczewska, Ewa, Wong, Alexander, Idriz, Nevin, Imamura, Michio, Rizzardini, Giuliano, Takaguchi, Koichi, Andreone, Pietro, Arbune, Manuela, Hou, Jinlin, Park, Sung Jae, Vata, Andrei, Cremer, Jennifer, Elston, Robert, Lukić, Tamara, Quinn, Geoff, Maynard, Lauren, Kendrick, Stuart, Plein, Helene, Campbell, Fiona, Paff, Melanie, Theodore, Dickens

“…In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface…”
Get full text

The most difficult to cure with pangenotypic regimens HCV infected population by Flisiak, Robert, Berak, Hanna, Parfieniuk-Kowerda, Anna, Dybowska, Dorota, Tomasiewicz, Krzysztof, Sitko, Marek, Zarębska-Michaluk, Dorota, Mazur, Włodzimierz, Janczewska, Ewa, Klapaczynski, Jakub, Jaroszewicz, Jerzy

Get full text

THU-215 - The most difficult to cure with pangenotypic regimens HCV infected population by Flisiak, Robert, Berak, Hanna, Parfieniuk-Kowerda, Anna, Dybowska, Dorota, Tomasiewicz, Krzysztof, Sitko, Marek, Zarębska-Michaluk, Dorota, Mazur, Włodzimierz, Janczewska, Ewa, Klapaczynski, Jakub, Jaroszewicz, Jerzy

Get full text